Clinical Trial Update: Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD [Phase 4]

View source ↗

Summary

This clinical trial update describes a Phase 4 study examining how genetic variation in carboxylesterase 1 affects methylphenidate response in ADHD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Methylphenidate (Methylphenidate)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: ADHD, Attention Deficit Hyperactivity Disorder | Phase 4 | Status: RECRUITING